Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease
نویسندگان
چکیده
منابع مشابه
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
BACKGROUND Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy, yet real-world switching data are currently limited. Here, we assess the effectiveness and safety of switching to CT-P13 from infliximab refere...
متن کاملEfficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
OBJECTIVES To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions. METHODS This open-label extension study recruited patients with RA who had completed the 54-week, randomised, parallel-group study comparing ...
متن کاملEfficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
OBJECTIVES To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS). METHODS This open-label extension study recruited patients with AS who completed a 54-week, randomised controlled study comparing CT-P13 with RP (PLANETAS). CT-P13 (5 mg/kg) was administered in...
متن کاملThe Role of Infliximab Biosimilar CT-P13 in Inflammatory BowelDisease
The advent of targeted biologic therapies for debilitating disorders such as Crohn’s disease (CD) and Ulcerative Colitis (UC) has changed management and significantly improved outcomes. However, biologic agents are expensive, and the introduction of biosimilar medications for the treatment of inflammatory bowel diseases presents a lower-cost alternative. In this review, the mechanism of action,...
متن کاملSafety of infliximab in patients suffering from inflammatory bowel disease.
Accessible online at: www.karger.com/dig Tumor necrosis factor-· (TNF-·) is a central cytokine in the inflammatory process associated with Crohn’s disease (CD). Infliximab, a chimeric IgG1 antibody directed against soluble and membrane-bound TNF-·, has shown efficacy both in luminal and fistulizing CD. It was approved in October 1998 by the US Food and Drug Administration for the treatment of m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Gastroenterology & Hepatology
سال: 2017
ISSN: 0954-691X
DOI: 10.1097/meg.0000000000000953